February 19, 2025 06:33 AM ESTUpdated 06:45 AM

Supernus’ stock sinks after placebo effect derails mid-stage depression study

Elizabeth Cairns

Senior biopharma journalist

The risk of drug development in the neuropsychiatric field is that the drug may work — but sometimes placebo does too. Supernus Pharmaceuticals became the latest …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Supernus’ stock sinks after placebo effect derails mid-stage depression study

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

FDA’s policy, communications staff likely to be among agency’s 3,500 staff cuts

Kennedy announces 10,000 job cuts at HHS, with major reductions expected at FDA, NIH and CDC

Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025

With tariffs on the way, generic drugmaking woes could hinder Trump’s reshoring plan

Merck details injectable Keytruda data as it awaits autumn FDA decision

FDA approves first drug for Prader-Willi syndrome, to tamp down insatiable hunger symptoms

Su­per­nus’ stock sinks af­ter place­bo ef­fect de­rails mid-stage de­pres­sion study

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

more like this

FDA’s pol­i­cy, com­mu­ni­ca­tions staff like­ly to be among agency’s 3,500 staff cuts

Kennedy an­nounces 10,000 job cuts at HHS, with ma­jor re­duc­tions ex­pect­ed at FDA, NIH and CDC

Ex­clu­sive: Met­sera CEO on what it takes to build an obe­si­ty biotech in 2025

With tar­iffs on the way, gener­ic drug­mak­ing woes could hin­der Trump’s reshoring plan

Mer­ck de­tails in­jectable Keytru­da da­ta as it awaits au­tumn FDA de­ci­sion

FDA ap­proves first drug for Prad­er-Willi syn­drome, to tamp down in­sa­tiable hunger symp­toms

Supernus’ stock sinks after placebo effect derails mid-stage depression study

FDA’s policy, communications staff likely to be among agency’s 3,500 staff cuts

Kennedy announces 10,000 job cuts at HHS, with major reductions expected at FDA, NIH and CDC

Exclusive: Metsera CEO on what it takes to build an obesity biotech in 2025

With tariffs on the way, generic drugmaking woes could hinder Trump’s reshoring plan

Merck details injectable Keytruda data as it awaits autumn FDA decision

FDA approves first drug for Prader-Willi syndrome, to tamp down insatiable hunger symptoms